Barclays PLC Reduces Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Barclays PLC lowered its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 4.8% in the fourth quarter, HoldingsChannel reports. The firm owned 113,038 shares of the company’s stock after selling 5,655 shares during the period. Barclays PLC’s holdings in Arcus Biosciences were worth $1,684,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in shares of Arcus Biosciences by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock valued at $668,000 after purchasing an additional 1,117 shares in the last quarter. R Squared Ltd bought a new position in Arcus Biosciences during the 4th quarter valued at $26,000. Teacher Retirement System of Texas grew its holdings in Arcus Biosciences by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock worth $223,000 after acquiring an additional 2,410 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Arcus Biosciences by 11.2% during the 4th quarter. Handelsbanken Fonder AB now owns 24,800 shares of the company’s stock worth $369,000 after acquiring an additional 2,500 shares in the last quarter. Finally, WINTON GROUP Ltd increased its position in shares of Arcus Biosciences by 5.4% in the 4th quarter. WINTON GROUP Ltd now owns 72,310 shares of the company’s stock worth $1,077,000 after purchasing an additional 3,730 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CEO Terry J. Rosen purchased 19,800 shares of Arcus Biosciences stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at $26,001,348.80. The trade was a 0.78 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Yasunori Kaneko purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was acquired at an average cost of $10.06 per share, with a total value of $201,200.00. Following the purchase, the director now owns 28,400 shares of the company’s stock, valued at approximately $285,704. This represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on RCUS. Barclays reduced their price target on shares of Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 23rd. Bank of America reduced their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Morgan Stanley lowered their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $28.38.

Arcus Biosciences Trading Up 5.8 %

NYSE:RCUS opened at $9.12 on Friday. The firm has a market capitalization of $958.86 million, a P/E ratio of -2.90 and a beta of 1.54. The business has a 50 day simple moving average of $8.58 and a 200 day simple moving average of $12.75. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $18.98.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. Equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.